Yige Wu

Yige Wu

Auto-generated profile, based on publicly available information

Yige Wu

Department of Medicine, Washington University in St. Louis, St. Louis, Missouri

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
YWYige Wu
Yige Wu
SCSiqi Chen
Siqi Chen
XYXiaolu Yang
Xiaolu Yang
KSKazuhito Sato
Kazuhito Sato
PLPreet Lal
Preet Lal
FCFeng Chen
Feng Chen
Current treatment approaches for renal cell carcinoma (RCC) face challenges in achieving durable tumor responses due to tumor heterogeneity and drug resistance. Combination therapies that leverage tumor molecular profiles could offer an avenue for enhancing treatment efficacy and addressing the limitations of current therapies. To identify effective strategies for treating RCC, we selected ten drugs guided by tumor biology to test in six RCC patient-derived xenograft (PDX) models. The multitargeted tyrosine kinase inhibitor (TKI) cabozantinib and mTORC1/2 inhibitor sapanisertib emerged as the most effective drugs, particularly when combined. The combination demonstrated favorable tolerability and inhibited tumor growth or induced tumor regression in all models, including two from patients who experienced treatment failure with FDA-approved TKI and immunotherapy combinations. In cabozantinib-treated samples, imaging analysis revealed a significant reduction in vascular density, and single-nucleus RNA sequencing (snRNA-seq) analysis indicated a decreased proportion of endothelial cells in the tumors. SnRNA-seq data further identified a tumor subpopulation enriched with cell-cycle activity that exhibited heightened sensitivity to the cabozantinib and sapanisertib combination. Conversely, activation of the epithelial–mesenchymal transition pathway, detected at the protein level, was associated with drug resistance in residual tumors following combination treatment. The combination effectively restrained ERK phosphorylation and reduced expression of ERK downstream transcription factors and their target genes implicated in cell-cycle control and apoptosis. This study highlights the potential of the cabozantinib plus sapanisertib combination as a promising treatment approach for patients with RCC, particularly those whose tumors progressed on immune checkpoint inhibitors and other TKIs.Significance: The molecular-guided therapeutic strategy of combining cabozantinib and sapanisertib restrains ERK activity to effectively suppress growth of renal cell carcinomas, including those unresponsive to immune checkpoint inhibitors.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
ESErik Storrs
Erik Storrs
DZDaniel Cui Zhou
Daniel Cui Zhou
MWMichael C. Wendl
Michael C. Wendl
MWMatthew A. Wyczalkowski
Matthew A. Wyczalkowski
AKAlla Karpova
Alla Karpova
LDLi Ding
Li Ding
The use of single-cell methods is expanding at an ever-increasing rate. While multiple algorithms address the task of cell classification, they are limited in terms of cross platform compatibility, reliance on the availability of a reference dataset, and classification interpretability. Here, we introduce Pollock, a suite of algorithms for cell type identification that is compatible with popular single cell methods and analysis platforms, provides a series of pretrained human cancer reference models, and reports interpretability scores that identify the genes that drive cell type classifications. Our model combines two important approaches, one each from machine learning and deep learning: a variational autoencoder (VAE) and random forest classifier, to make cell type predictions. Pollock is highly versatile, being available as a command line tool, Python library (with scanpy integration), or R library (with Seurat integration), and can be installed as a conda package, or in containerized form via Docker. To allow for easier pan-disease and pan-tissue analyses, Pollock also ships with a library of pretrained cancer type specific and agnostic modules that were trained on expertly-curated single cell data that are ready to “plug and play” with no additional annotation or training required. Conversely, Pollock also allows for the training of custom classification modules, if an annotated reference single cell dataset is available. These pretrained models were fitted on manually curated and annotated single cell data from eight different cancer types spanning three single cell technologies (scRNA-seq, snRNA-seq, and snATAC-seq). Pollock also provides feature importance scores that allow for cell type classifications to be traced back to the genes influencing a particular cell type classification, further promoting biological interpretability. These scores could allow for new, technology-specific biomarker discovery. We also demonstrate the utility of Pollock by applying it in a pan-cancer single cell immune analysis. Citation Format: Erik Storrs, Daniel Cui Zhou, Michael C. Wendl, Matthew A. Wyczalkowski, Alla Karpova, Liang-Bo Wang, Yize Li, Austin Southard-Smith, Reyka G. Jayasinghe, Lijun Yao, Ruiyang Liu, Yige Wu, Nadezhda V. Terekhanova, Houxiang Zhu, John M. Herndon, Feng Chen, William E. Gillanders, Ryan C. Fields, Li Ding. Pollock: Fishing for cell states [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1932.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
CMChia-Kuei Mo
Chia-Kuei Mo
YWYige Wu
Yige Wu
TNTerekhanova Nadezhda
Terekhanova Nadezhda
CWCaravan Wagma
Caravan Wagma
PLPreet Lal
Preet Lal
FCFeng Chen
Feng Chen
Next-generation sequencing enabled molecular landscaping and the discovery of novel tumor markers in ccRCC. However, the spatial relationships and histological features of the tumor microenvironment were lost during this process. Combining snRNA-seq, snATAC-seq, Spatial Transcriptomics (ST) technology, and immunofluorescence labeling, we discovered novel ccRCC progression tumor markers, and uncovered their spatial dependent expression pattern in both human ccRCC tumors and patient-derived xenograft (PDX). Using snRNA-seq and snATAC-seq, novel tumor progression markers such as NDRG1, MGST1, ABCC3 and PCSK6 were discovered, and their expressions were validated in ST. We found that one of the key novel tumor markers, CP, exhibited specific spatial expression patterns on tissue slides. The elevation of CP expression region is associated with a higher degree of hyalinization in ccRCC human tumor samples. Similarly, using immunofluorescence labeling, we validated the co-expression of CP and PCSK6 canonical ccRCC marker CA9. Overall, this study revealed novel ccRCC progression markers and linked their spatial expression pattern with histological features. Citation Format: Chia-Kuei Mo, Yige Wu, Terekhanova Nadezhda, Caravan Wagma, Preet Lal, Siqi Chen, Nataly Naser AL Deen, Ruiyang Liu, Yanyan Zhao, Kazuhito Sato, Lijun Yao, Mamatha Serasanambati, Andrew Shinkle, Reyka G. Jayasinghe, Li Ding, Feng Chen. Spatial transcriptomic profiling of progression markers in clear cell renal cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2025.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
ISIlya Strunilin
Ilya Strunilin
YWYige Wu
Yige Wu
RLRuiyang Liu
Ruiyang Liu
WCWagma Caravan
Wagma Caravan
FCFeng Chen
Feng Chen
LDLi Ding
Li Ding
Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, with 5-year mortality of 25%. The molecular landscape of ccRCC has been elucidated by a number of next generation sequencing studies and complemented by recent global proteome and phosphoproteome results. However, a limitation of such studies is the mixture of signals from distinct cell populations, presenting challenges to subsequent interpretation. As a remedy, single nuclei RNA-seq (snRNA-seq) is able to dissect distinct cell populations and map their differential expression patterns. Using snRNA-seq from 30 ccRCC tumor samples, we identified distinct genetic pathways associated with survival in the TCGA patient cohort (525 patients) in multiple cell types, including immune and stromal components. Prognostic value of pathways was confirmed in an independent cohort with 130 patients. Multiple cancer cell-specific pathways were related to metabolism, suggesting that certain metabolites are less abundant in high-risk tumors. Using data from two independent large-scale metabolism ccRCC studies, we found metabolites’ levels changing in accordance with our predictions, when comparing low-risk to high-risk ccRCC tumors. Citation Format: Ilya Strunilin, Yige Wu, Ruiyang Liu, Wagma Caravan, Feng Chen, Li Ding. Defining cell type-specific pathways in both cancer and tumor-microenvironment cells that impact survival of clear cell renal carcinoma patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 4017.